Although some discrepancies exist in the literature that can be partially explained by the nature of the stress inducer, several recent reports combining both genetic and pharmacological manipulation of Epac1, provided proof-of-concept for the therapeutic effectiveness of inhibiting Epac1 activity in cardiac disease using small-molecule pharmacotherapy. Here, RAPGEF3 is linked to heart disorder.